| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | prednisolone (Prednisolone Dompé®) |
| Formulation | 1.0 mg/ml oral solution |
| Reference number | 2339 |
| Indication | Use in rheumatological disorders and connective tissue diseases such as rheumatoid arthritis (for primary chronic disease and maintenance therapy), systemic lupus erythematosus (non-organ threatening disease) and mild-moderate juvenile dermatomyositis; severe or debilitating allergic conditions, not treatable in a conventional manner such as bronchial asthma in children, bronchial asthma in adults (for maintenance therapy); sarcoidosis in children and for maintenance therapy in adults; and acquired haemolytic anaemia (autoimmune, for maintenance therapy) |
| Company | Dompe farmaceutici SpA |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 05/05/2015 |